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at least one 16Val allele among never smokers encompass 
reduced BC risk (OR 0.14, 95 % CI 0.03–0.63; P = 0.01) 
(P heterogeneity = 0.04).
Conclusions this study supports hypothesis that GSTM1 
null genotype may be a moderate BC risk factor. the gene–
gene and gene–environment interactions associated with 
combined GSTP1/GSTT1 and combined GSTT1/SOD2 
genetic polymorphisms along with cigarette smoking habit 
may play a significant role in BC risk modulation.
Keywords nRF2 · glutathione S-transferase · 
superoxide dismutase · genetic polymorphism · Urinary 
bladder cancer
Introduction
Urinary bladder cancer (BC) is a common disease with high 
prevalence in the developed countries in comparison with 
the rest of the world. BC occurs more frequently in men 
than in women, making it the fourth most common cancer 
among men and the eighth among women in europe (glO-
BOCan 2008). Incidence of BC in Poland is slightly lower 
than the average incidence in Western and southern europe, 
but it has been increasing rapidly. the majority (90–95 %) 
of BC—transitional cell carcinoma—comprises superficial 
tumors (70 %), which are usually low-grade and non-mus-
cle-invasive bladder cancer (nMIBC) at the stage ta/t1, 
and the second one has the form of muscle-invasive disease 
(MIBC) at the stages from t2 to t4 (30 %). the overall rate 
of recurrence for nMIBC ranges from 60 to 70 %, and the 
overall rate of progression to a higher stage or grade and 
metastasis from 20 to 30 % (grotenhuis et al. 2010).
several well-defined BC risk factors have been 
identified, including tobacco smoke (encompassing 
Abstract 
Purpose nRF2 transcription factor is involved in modu-
lation of various antioxidant and metabolic genes and, 
therefore, may modulate anti-carcinogenic potential. asso-
ciation between polymorphisms of NRF2 and five nRF2-
regulated genes and urinary bladder cancer (BC) risk was 
analyzed.
Methods the study group included 244 BC patients, 
while the control group comprised 365 individuals with 
no evidence of malignancy. genotyping of GSTM1 (dele-
tion), GSTT1 (deletion), GSTA1 −69C/t (rs3957357), 
GSTP1 Ile105Val (rs1695), SOD2 ala16Val (rs4880) and 
NRF2 −617C/a (rs6721961) in blood genomic Dna was 
performed by means of real-time PCR assays. the associa-
tions between gene polymorphism and BC risk were com-
puted by logistic regression.
Results the frequency of GSTA1, GSTP1, SOD2 and 
NRF2 genotypes did not differ in both groups. a signifi-
cantly higher BC risk was associated with GSTM1 null 
genotype after adjusting to age, sex and smoking habit 
(OR 1.85, 95 % CI 1.30–2.62; P = 0.001). GSTT1 null 
(OR 0.50, 95 % CI 0.31–0.81; P = 0.005) and GSTP1 Val-
105Val (OR 0.52, 95 % CI 0.27–0.98; P = 0.04) genotypes 
were associated with reduced BC risk separately or in com-
bination (OR 0.24, 95 % CI 0.11–0.51; P < 0.0001) (P het-
erogeneity = 0.01). Combined GSTT1 null and SOD2 with 
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approximately 30–50 % BC risk, similar BC in men and 
women), aromatic amines, polycyclic aromatic hydro-
carbons (Pahs), dietary nitrites and nitrates, chlorin-
ated hydrocarbons, coal, alkylating agents, arsenic, diesel 
engine exhaust. In addition, BC was one of the first cancers 
shown to be industrially associated with aniline dye indus-
try (Cohen 1998; IaRC 2012; Volanis et al. 2010). BC risk 
has also been linked with coffee consumption and overall 
fluid consumption, including chlorinated water. the protec-
tive effect on BC risk was attributed to fruit and vegetables 
consumption and to high selenium status (Brinkman and 
Zeegers 2008).
Chemically induced urinary bladder carcinogenesis in 
rodents showed the importance of nuclear factor (eryth-
roid-derived 2)-like 2 (nRF2 or nFe2l2)-regulated sign-
aling pathway (Iida et al. 2004, 2007; Jiang et al. 2009). 
Moreover, urinary bladder in rats was the most sensitive 
organ to gst enzyme induction after administration of 
isothiocyanates, the chemical compounds which contribute 
well-known nRF2 inductors (Munday and Munday 2002). 
Various studies have shown that nRF2 signaling path-
way is the major mechanism, which controls the expres-
sion of target genes with antioxidant response element 
(aRe) sequence in their promoters. Under basal condi-
tions, transcription factor nRF2 is localized in the cyto-
plasm and regulated by Kelch-like eCh-associated protein 
1 (KeaP1). alteration of redox balance leads to nRF2 
translocation to the nucleus and activation of aRe-con-
taining genes. nRF2-modulated antioxidant that involved 
in xenobiotic metabolism enzymes may protect against 
oxidants and electrophilic agents and therefore may con-
tribute to the enhancement of anti-carcinogenic activity 
(Kensler and Wakabayashi 2010; Maher and Yamamoto 
2010). the role of specific nRF2-regulated metabolic 
and antioxidant genes in urinary bladder tissue has been 
intensively investigated. It was found that highly meta-
static human bladder cells displayed significantly higher 
mitochondrial superoxide dismutase (sOD2) levels and 
activities compared with the non-metastatic parental cell 
line (hempel et al. 2009). several studies have shown 
that glutathione S-transferase P1 (gstP1), gstM1 and 
gstt1 are highly expressed in urinary bladder tissues 
and showed significantly higher activity and expression of 
these enzymes in bladder tumors than in normal uroepithe-
lium (Pljesa-ercegovac et al. 2011; savic-Radojevic et al. 
2007; simic et al. 2005). the fact that human urinary blad-
der tumors are characterized by up-regulation of NRF2 
expression in comparison with adjacent non-cancer tissues 
is also worth attention (Kawakami et al. 2006).
Individual differences in biotransformation of BC car-
cinogens and in scavenging of reactive oxygen and nitro-
gen species are quoted as one of the proposed mechanisms 
in BC etiology. It was observed that cytoprotective genes 
very often possess aRe sequence and therefore can be 
modulated by nRF2 transcription factor. For the last two 
decades, functional polymorphisms of GSTM1 and GSTT1 
(gene deletion), GSTP1 Ile105Val (rs1695) affecting gene 
and enzyme expression, enzyme activity or substrate 
affinity have been analyzed in relation to BC risk in vari-
ous ethnic groups. lack of the enzyme due to gene dele-
tion was observed in case of GSTM1 (Fryer et al. 1993) 
and GSTT1 (Pemble et al. 1994). Minor GSTP1 105Val 
alleles can be associated with lower enzymatic gst activ-
ity than major GSTP1 105Ile alleles, due to changes in 
hydrophobic substrate active center (Watson et al. 1998). 
Functional significance of GSTA1 −69C/t (rs3957357) 
polymorphism in promoter region results in differential 
expression with lower transcriptional activation and lower 
gst activity of minor GSTA1 −69t allele than major 
GSTA1 −69C allele (Coles et al. 2001). SOD2 polymor-
phism (rs4880) is associated with ala to Val amino acid 
replacement in codon 16 which results in a conformational 
change from α-helix to β-sheet in the protein secondary 
structure and lower mitochondrial import efficiency of 
the pre-matured sOD2 with SOD2 16Val allele than the 
SOD2 16ala allele (shimoda-Matsubayashi et al. 1996; 
sutton et al. 2003). the functional significance of NRF2 
−617C/a (rs6721961) genetic polymorphism in promoter 
region is still unraveled. Marzec et al. have found that 
NRF2 −617a allele presents significantly lower luciferase 
activity of promoter construct containing single nucleotide 
polymorphism relative to the wild type at this locus (NRF2 
−617CC) (Marzec et al. 2007). Recently, hua et al. (2010) 
have presented opposite results showing higher luciferase 
activity of NRF2 −617a than NRF2 −617C construct and 
suggested interaction with triplet repeat polymorphism of 
NRF2 (CCg)4or5.
Meta- or pooled analyses of gst genetic polymor-
phism and BC risk, indicated that GSTM1 null genotype 
may be the moderate risk factor (Jiang et al. 2011; Zhang 
et al. 2011a, b), followed by GSTP1 105Val allele (Kellen 
et al. 2007; Wu et al. 2012). noteworthy, slight increase 
in the risk was observed in case of GSTT1 null genotype 
(gong et al. 2012; Zeng et al. 2010). Unfortunately, only 
five studies that focus on the role of mitochondrial super-
oxide dismutase (SOD2) (rs4880) genetic polymorphism 
in BC risk are available (Cengiz et al. 2007; hung et al. 
2004; Kucukgergin et al. 2012; terry et al. 2005; Vineis 
et al. 2007) and two studies investigated the role of GSTA1 
(rs3957357) (Komiya et al. 2005; Matic et al. 2013), 
whereas studies on NRF2 (rs6721961) genetic polymor-
phisms in urinary BC risk are still missing. therefore, the 
aim of this study was to analyze single and combined pol-
ymorphisms of NRF2 and nRF2 target genes and BC risk, 
also in relation to potential modifying factors such as age, 
sex and smoking habit.




the study group consisted of, in total, 244 BC patients, 
including 61 females and 183 males, aged 22–92 years 
(mean age 66.5 years) recruited from the I Department 
of Urology, Medical University in lodz, Military teach-
ing hospital (central Poland) over the years 2007–2012. 
the BC patients with previous history of other neo-
plasms were excluded from the study. all BC patients 
underwent transurethral resection and they had histo-
pathologically confirmed nMIBC or MIBC at various 
tumor t stage and degree of g neoplasm. Due to insuf-
ficient data regarding t stage of BC patients, only grade 
g was included in the analyses. the population-based 
control group of individuals with no evidence of malig-
nancy comprised 365 individuals, including 67 females 
and 298 males, aged 27–83 (mean age 61.3 years). they 
were patients of the Primary health service at this hos-
pital and volunteers from the nofer Institute of Occu-
pational Medicine. the ethics Committee for scientific 
Research at nofer Institute approved the study protocol, 
and a written informed consent was obtained from each 
individual before taking part in the study. Venous blood 
samples were collected into s-Monovette® heparinized 
test tubes, preserved and stored at −80 °C until Dna 
isolation. Participants of the study filled in a question-
naire that provided information on demographic char-
acteristics and smoking history with categories of non-, 
current and ex-smokers. the individuals who declared 
quitting smoking 5 years and less before the interview 
were classified as current smokers. Characteristics of the 
study subjects are presented in table 1.
genotyping
genomic Dna was isolated from buffy coats using 
QIaamp Dna Blood Mini Kit (Qiagen), in accordance 
with the manufacturer’s instructions. genotyping of GSTM1 
(deletion), GSTT1 (deletion), GSTA1 −69C/t (rs3957357), 
GSTP1 Ile105Val (rs1695), SOD2 ala16Val (rs4880) and 
NRF2 −617C/a (rs6721961) in blood genomic Dna was 
performed by means of real-time PCR assays. Details of the 
analyzed genetic polymorphisms are presented in table 2. 
Primers for end point real-time PCR (GSTM1 and GSTT1) 
were in accordance with norskov et al. (2009). hRM 
(GSTA1) assay was designed by the use of Beacon Designer 
7.01 (PReMIeR Biosoft Int., Palo alto, Ca, Usa) based 
on the genBank® genetic sequence database with prim-
ers: (forward) 5′-tgaaatgtgtgggagtggCtttt-3′, 
(reverse) 5′-CgtCCtggCtCgaCaaCtg-3′. GSTM1 and 
GSTT1 genotyping was performed using Faststart sYBR 
green Master (Roche, Basel, swizerland) and GSTA1 using 
ssoFast™ evagreen® supermix (Bio-Rad laboratories, 
Inc., hercules, Ca, Usa). allelic discrimination of GSTP1, 
SOD2 genotypes was performed by the use of taqMan® pre-
design snP (single nucleotide polymorphism) assays and 
taqMan® custom snP assay for NRF2 genetic polymor-
phism, using taqMan® genotyping Master Mix (life tech-
nologies, Carlsbad, Ca, Usa). genotyping was performed 
using the control Dna samples with known genotypes 
and a negative control; 10 % of the samples were blindly 
selected for the re-tests with 100 % concordant results.
Table 1  Characteristics of urinary bladder cancer patients and con-
trols
a
 Missing age for eight BC patients and two controls
b
 Missing smoking status for six BC patients and two controls
c






Mean age ± sD 
(min–max)a
66.5 ± 10.5 
(22–92)
61.3 ± 10.4 
(27–83)
<0.0001
never smokersb 65 (27.3 %) 119 (32.8 %) <0.0001
Current smokersc 103 (43.3 %) 196 (54.0 %)
ex-smokers 70 (29.4 %) 48 (13.2 %)
Male 183 (75.0 %) 298 (81.6 %) 0.05
Female 61 (25.0 %) 67 (18.4 %)
grade g1c 118 (54.1 %) – –
grade g2 61 (28.0 %)
grade g3 39 (17.9 %)
Table 2  allelic frequencies in 
urinary bladder cancer patients 
and controls
a
 dbsnP from http://www.ncbi.
nlm.nih.gov/projects/snP
b
 MAF minor allele frequency
c
 test of departure from hWe
gene name dbsnPa nucleotide/amino acid 
change
MaFb χ2c P valuec MaFb χ2c P valuec
BC patients Controls
GSTM1 – Deletion – –
GSTT1 – Deletion – –
GSTA1 rs3957357 −69C/t 0.38 0.25 0.62 0.40 1.19 0.26
GSTP1 rs1695 562a/g/exon 5, Ile105Val 0.30 0.91 0.34 0.33 0.17 0.68
SOD2 rs4880 −9C/t/exon 1, ala16Val 0.47 2.22 0.14 0.51 4.82 0.03
NRF2 rs6721961 −617C/a 0.12 0.17 0.68 0.12 1.41 0.24
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statistical analysis
arithmetic means with standard deviations and frequen-
cies of the basic characteristics were calculated. the Pear-
son’s chi-square test was calculated in order to compare the 
genotype frequencies distribution among the BC patients 
and controls. a free web-page software based on chi-square 
test was used to determine any discrepancies of distribution 
from hardy-Weinberg equilibrium (hWe) in BC patients 
and controls (Rodriguez et al. 2009). the associations 
between single and combined gene polymorphism and BC 
risk [odds ratio (OR) with 95 % confidence interval (CI)] 
were computed by the use of logistic regression. the co-
dominant model for heterozygous and variant homozygous 
genotype and dominant model grouping heterozygous with 
homozygous minor alleles were analyzed. GSTM1 positive, 
GSTT1 positive genotypes and the major homozygotes for 
GSTA1, GSTP1, NRF2, SOD2 were set as a reference group. 
the list of variant genotypes associated with potential risk 
of BC includes GSTM1 null, GSTT1 null, GSTA1 −69Ct 
and −69tt, GSTP1 Val105Val and Ile105Val, SOD2 ala-
16Val and Val16Val, NRF2 −617Ca and −617aa. so as 
to adjust to the factors that may influence the disease status, 
age, sex and smoking habit were taken into account. then, 
chi-square tests of heterogeneity were carried out. the value 
of P < 0.05 for the group characteristics was considered 
as the value representing statistical significance. statistical 
analyses were performed using stata11.0 (stataCorp lP, 
College station, tX, Usa) and graphPad Prism® version 
5.04 (graphPad software, Inc., la Jolla, Ca, Usa).
Results
the BC patients were significantly older than the individu-
als from the control group (66.5 vs. 61.3 years, P < 0.0001). 
the investigated groups also differed in terms of sex ratio 
(P = 0.05) and smoking habit (P < 0.0001). there were 
more current smokers in the control group than in the BC 
patients (54.0 vs. 43.3 %), while ex-smokers were more 
frequent in the BC group than in the control group (29.4 
vs. 13.2 %). the risk of BC among individuals who ever 
smoked was 1.70 (95 % CI 1.08–2.69; P = 0.03), estimated 
after adjusting for age and gender. low, g1 grade of uri-
nary bladder tumor was present in 118 of the BC patients, 
while higher, g2 and g3 grades in 61 and 39 patients, 
respectively (table 1).
all genotypes were in hWe in the BC patients and 
controls (P < 0.001) (table 2). homozygous deletion of 
GSTM1 gene was more frequent in the BC patients than in 
controls (61.1 vs. 45.2 %, P < 0.0001), while homozygous 
deletion of GSTT1 gene was more rarely observed in the 
BC patients than in controls (12.4 vs. 21.1 %, P = 0.006). 
a significantly higher risk of BC was associated with 
GSTM1 null genotype after adjusting to age, sex and smok-
ing habit (OR 1.85, 95 % CI 1.30–2.62; P = 0.001). GSTT1 
null genotype was associated with reduced BC risk (OR 
0.50, 95 % CI 0.31–0.81; P = 0.005). the frequency of 
GSTA1, GSTP1, SOD2 and NRF2 genotypes did not dif-
fer significantly between both groups, but lower prevalence 
of minor homozygotes was observed in the BC patients in 
comparison with the controls. GSTP1 Val105Val genotype 
was associated with significantly lower BC risk (OR 0.52, 
95 % CI 0.27–0.98, P = 0.04). that association was not 
found in the individuals with at least one minor GSTP1 
105Val allele (OR 0.81, 95 % CI 0.57–1.14; P = 0.23) 
(table 3).
gene–gene analyses of genotypes with a combination 
of 15 double genotypes and 18 triple genotypes showed 
significantly increased BC risk associated with GSTM1 
null and GSTA1 −69Ct + −69tt genotype (OR 1.56, 
95 % CI 1.08–2.26; P = 0.02). significantly reduced BC 
risk was related to GSTT1 null and SOD2 ala16Val + Val-
16Val genotype (OR 0.55, 95 % CI 0.32–0.96; P = 0.04) 
and GSTP1 Ile105Val + Val105Val and GSTT1 null and 
SOD2 ala16Val + Val16Val genotype (OR 0.22, 95 % CI 
0.09–0.56; P = 0.001). however, the significant impact of 
gene–gene interaction on BC risk was confirmed only in 
case of GSTP1 and GSTT1 genetic polymorphisms (P het-
erogeneity = 0.01) with reduced BC risk for GSTT1 null 
and GSTP1 Ile105Val + Val105Val combined genotype 
(OR 0.24, 95 % CI 0.11–0.51; P < 0.0001) (table 4).
single and combined genotypes association with BC 
risk did not vary in groups divided into men and women, 
and in relation to age and tumor grade g (data not shown). 
however, a possible association of those genotypes and BC 
risk stratified by reported smoking status was observed. 
GSTM1 null genotype was associated with BC risk only in 
current smokers (OR 1.80, 95 % CI 1.09–2.97; P = 0.02), 
but in case of non-smokers and ex-smokers, the estimated 
risk was similar, although not significant (OR 1.84, 95 % 
CI 0.93–3.64; P = 0.08 and OR 2.04, 95 % CI 0.95–4.36; 
P = 0.08, respectively). BC risk associated with GSTT1 
null genotype was considerably reduced in non-smokers 
in comparison with current smokers with GSTT1 positive 
genotype carriers (OR 0.26, 95 % CI 0.09–0.74; P = 0.01 
vs. OR 0.47, 95 % CI 0.23–0.99; P = 0.05). Moreover, sev-
eral combined variant genotypes among non-smokers were 
associated with a significantly reduced BC risk: GSTT1 
null and GSTP1 Ile105Val + Val105Val (OR 0.07, 95 % CI 
0.01–0.57; P = 0.01); GSTP1 Ile105Val + Val105Val and 
NRF2 −617Ca + −617aa (OR 0.29, 95 % CI 0.08–0.98; 
P = 0.05); GSTT1 null and SOD2 ala16Val + Val16Val 
(OR 0.14; 95 % CI 0.03–0.63; P = 0.01). the combined 
GSTM1 null and NRF2 −617Ca + −617aa genotypes 
among current smokers were linked with significantly 
1727J Cancer Res Clin Oncol (2014) 140:1723–1731 
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higher BC risk (OR 2.52, 95 % CI 1.17–5.41; P = 0.02). 
additionally, a significant impact of smoking habit was 
confirmed only in case of combined GSTT1 and SOD2 
genetic polymorphisms in never smokers (P heterogene-
ity = 0.04) (table 5).
Discussion
specific carcinogens, including occupationally and environ-
mentally derived arylamines and Pahs, require metabolic 
activation to induce BC. the postulated mechanism of 
their adverse effect on uroepithelium is based on activities 
of specific metabolites synthesized in the liver by phase I 
enzymes and then transported via blood or urine to urinary 
bladder (gundert-Remy et al. 2013). however, it was found 
that local xenobiotics metabolism and also cytoprotective 
activity may directly influence carcinogenesis process in 
urinary bladder epithelial cells. the role of nRF2 transcrip-
tion factor and nRF2-modulated antioxidant and metabolic 
enzymes against oxidants and electrophilic agents has been 
widely investigated. Results revealed that human urinary 
Table 3  Distribution of 
genotypes and urinary bladder 
cancer risk
a
 Differences in genotypes 
distribution
b
 adjusted to age, sex and 
smoking habit
c
 genotyping failure for two 
patients
d
 genotyping failure for one 
patient
e
 genotyping failure for one 
control
genotype BC patients n (%) Controls n (%) P valuea OR (95 % CI)b P value
GSTM1 positive 95 (38.9) 200 (54.8) <0.0001 Ref.
 null 149 (61.1) 165 (45.2) 1.85 (1.30–2.62) 0.001
GSTT1 positivec 212 (87.6) 288 (78.9) 0.006 Ref.
 null 30 (12.4) 77 (21.1) 0.50 (0.31–0.81) 0.005
GSTA1 −69CCd 92 (37.9) 137 (37.5) 0.49 Ref.
 −69Ct 118 (48.6) 165 (45.2) 0.99 (0.69–1.44) 0.95
 −69tt 33 (13.6) 63 (17.3) 0.75 (0.45–1.27) 0.29
 -69t 151 (62.1) 228 (62.5) 0.92 (0.65–1.32) 0.66
GSTP1 Ile105Ile 116 (47.5) 160 (43.8) 0.42 Ref.
 Ile105Val 109 (44.7) 166 (45.5) 0.88 (0.61–1.26) 0.47
 Val105Val 19 (7.8) 39 (10.7) 0.52 (0.27–0.98) 0.04
 105Val 128 (52.5) 205 (56.2) 0.81 (0.57–1.14) 0.23
SOD2 ala16alae 74 (30.3) 98 (26.9) 0.45 Ref.
 ala16Val 110 (45.1) 161 (44.2) 0.90 (0.60–1.36) 0.62
 Val16Val 60 (24.6) 105 (28.9) 0.79 (0.50–1.25) 0.32
 16Val 170 (69.7) 266 (73.1) 0.86 (0.60–1.26) 0.45
NRF2 −617CC 191 (78.3) 283 (77.5) 0.89 Ref.
 −617Ca 49 (20.1) 74 (20.3) 0.97 (0.64–1.49) 0.91
 −617aa 4 (1.6) 8 (2.2) 0.49 (0.12–1.94) 0.31
 −617a 53 (21.7) 82 (22.5) 0.92 (0.61–1.34) 0.68
Table 4  Combined genotypes associated with urinary bladder cancer risk
a
 Variant genotypes grouping heterozygous with homozygous minor alleles and GSTM1 null, GSTT1 null genotypes; reference genotypes group-
ing the remaining combination of major, minor and null alleles; the number of subjects may vary from investigated individuals due to GSTT1 
and GSTA1 genotyping failure
b
 adjusted to age, sex and smoking habit
c
 P heterogeneity = 0.01
genotypea BC patients n (%) Controls n (%) P value OR (95 % CI)b P value
GSTM1xGSTA1 150 (61.7) 265 (72.6) 0.005 Ref.
GSTM1xGSTA1 variant 93 (38.3) 100 (27.4) 1.56 (1.08–2.26) 0.02
GSTP1xGSTT1 233 (96.3) 320 (87.7) 0.0001 Ref.
GSTP1xGSTT1 variantc 9 (3.7) 45 (12.3) 0.24 (0.11–0.51) <0.0001
GSTT1xSOD2 220 (90.9) 311 (85.4) 0.05 Ref.
GSTT1xSOD2 variant 22 (9.1) 53 (14.6) 0.55 (0.32–0.96) 0.04
GSTP1xGSTT1xSOD2 226 (97.5) 334 (91.8) 0.003 Ref.
GSTP1xGSTT1xSOD2 variant 6 (2.5) 30 (8.2) 0.22 (0.09–0.56) 0.001
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bladder normal and malignant cells displayed high nRF2, 
sOD2 and gsts levels (hempel et al. 2009, Kawakami 
et al. 2006; Pljesa-ercegovac et al. 2011; savic-Radojevic 
et al. 2007; simic et al. 2005), which may suggest crucial 
role in urinary bladder carcinogenesis modulation. For 
example, the high content of gstP1 in urothelium may be 
responsible for the detoxification of benzo[a]pyrene dihy-
drodiol epoxide (simic et al. 2009), but at the same time, 
overexpression of gstP1, very often observed in urinary 
bladder tumors, may be linked with drug resistance dur-
ing chemotherapy (harbottle et al. 2001). Moreover, genes 
encoding these metabolic and antioxidant enzymes are 
known to be polymorphic and they may influence individ-
ual’s susceptibility to carcinogens in different ethnic popu-
lations (gong et al. 2012; Jiang et al. 2011; Marzec et al. 
2007; Vineis et al. 2007; Wu et al. 2012).
the association between GSTM1 and GSTT1 genetic pol-
ymorphisms, which are associated with lack of the specific 
gst isoenzyme and BC risk, has been intensively studied. 
It is worth to mention that in the present study, we selected 
those specific genetic polymorphisms, where the link 
between particular genotype and cancer risk was found to be 
strictly related to the biological relevance of polymorphism, 
influencing gene and protein expression or enzymatic activ-
ity. additionally, the reference group for GSTM1 and GSTT1 
analyses comprised individuals with one and two positive 
gene copies. this study shows that GSTM1 null genotype 
was associated with significantly increased BC risk (OR 
1.85, 95 % CI 1.30–2.62), while GSTT1 null genotype with 
the risk reduction (OR 0.50, 95 % CI 0.31–0.81). Recent 
two meta-analyses involving 26 (Zhang et al. 2011b) and 33 
(Jiang et al. 2011) studies showed that GSTM1 homozygous 
deletion was found to slightly influence BC risk in Cauca-
sians and asians, while in africans the influence of GSTM1 
null genotype on cancer risk was not observed. a multi-
stage, genome-wide association study including BC cases 
and controls of european descent confirmed GSTM1 dele-
tion with P = 4 × 10−11 and OR 1.47 as a candidate associa-
tion variant for BC (Rothman et al. 2010).
although in meta-analysis (Jiang et al. 2011) the effect 
of GSTM1 null genotype on BC risk was increased by 
smoking habit, the joint effect of GSTM1 null genotype 
was not greater among smokers, never and former smok-
ers in the present study, as well as in new england blad-
der cancer study (Moore et al. 2011). the marginal asso-
ciation between GSTT1 null genotype and BC risk in total 
ethnic population was found in a meta-analyses including 
37 studies (OR 1.12, 95 % CI 1.04–1.21) (Zeng et al. 2010) 
and in a recent meta-analysis of 50 studies (OR 1.15, 95 % 
CI 1.04–1.27) (gong et al. 2012). Opposite to that, in the 
individuals from central Poland, significantly lower preva-
lence of homozygous GSTT1 deletion in the BC patients 
was observed in comparison with the controls (12.4 % vs. 
21.1 %) with OR 0.50 (95 % CI 0.31–0.81). similarly, a 
recent study on BC patients living in Dortmund area 
showed fewer GSTT1 null genotypes among cases (17 %) 
than among controls (20 %) (Ovsiannikov et al. 2012). In 
the population from central Poland, the protective effect of 
Table 5  single and combined genotypes stratified by smoking status associated with urinary bladder cancer risk
a
 Variant genotypes grouping heterozygous with homozygous minor alleles and GSTM1 null, GSTT1 null genotypes; reference genotypes group-
ing the remaining combination of major, minor and null; the number of subjects may vary from investigated individuals due to GSTT1 and 
GSTA1 genotyping failure
b
 number of urinary bladder patients (BC) versus number of controls (Co)
c
 adjusted to age and sex
d
 P heterogeneity = 0.04
genotypea never smokers smokers ex-smokers
BC/Cob OR (95 % CI)c P value BC/Cob OR (95 % CI)c P value BC/Cob OR (95 % CI)c P value
GSTM1+ 22/61 Ref. 44/109 Ref. 29/29 Ref.
GSTM1 null 43/58 1.84 (0.93–3.64) 0.08 59/87 1.80 (1.09–2.97) 0.02 41/19 2.04 (0.95–4.36) 0.08
GSTT1+ 59/89 Ref. 90/156 Ref. 57/41 Ref.
GSTT1 null 6/30 0.26 (0.09–0.74) 0.01 11/40 0.47 (0.23–0.99) 0.05 13/7 1.23 (0.44–3.42) 0.40
GSTM1xNRF2 55/102 Ref. 87/179 Ref. 59/42 Ref.
GSTM1xNRF2 variant 10/17 0.69 (0.27–1.81) 0.46 16/17 2.52 (1.17–5.41) 0.02 11/6 1.30 (0.44–3.88) 0.63
GSTP1xNRF2 60/101 Ref. 95/180 Ref. 57/40 Ref.
GSTP1xNRF2 variant 5/18 0.29 (0.08–0.98) 0.05 8/16 0.93 (0.37–2.31) 0.87 13/8 1.10 (0.41–2.94) 0.85
GSTP1xGSTT1 64/99 Ref. 97/178 Ref. 66/41 Ref.
GSTP1xGSTT1 variant 1/20 0.07 (0.01–0.57) 0.01 4/18 0.37 (0.12–1.16) 0.09 4/7 0.32 (0.09–1.19) 0.09
GSTT1xSOD2 62/98 Ref. 94/168 Ref. 58/43 Ref.
GSTT1xSOD2 variantd 3/20 0.14 (0.03–0.63) 0.01 7/28 0.48 (0.20–1.17) 0.11 12/5 1.73 (0.56–5.36) 0.34
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GSTT1 null genotype observed in case of the whole popu-
lation was definitely more pronounced in non-smokers than 
in current smokers. two meta-analyses and new england 
bladder cancer study showed lack of association between 
GSTT1 null and cancer risk in relation to smoking status 
(gong et al. 2012; Moore et al. 2011; Zeng et al. 2010).
like in the case of GSTT1 genetic polymorphism, pre-
sent study also shows protective role of GSTP1 105Val 
variant alleles, associated with defected gst enzymatic 
activity, in BC risk. homozygotes with GSTP1 105Val 
allele were more frequent in the controls than in the BC 
patients (10.7 % vs. 7.8 %) and applied dominant model 
indicated that GSTP1 105Val allele carriers showed non-
significantly decreased BC risk (adjusted OR 0.81, 95 % 
CI 0.57–1.14). similarly, in the case–control study of BC 
patients from the Usa with 92.9 % of individuals of Cau-
casian origin in cases, and 97 % in controls, the frequency 
of GSTP1 105Val heterozygotes and homozygotes in con-
trols was higher than in BC cases (Cao et al. 2005). how-
ever, a meta-analysis and pooled-analysis indicated that 
GSTP1 polymorphism is the modest risk factor for BC with 
unadjusted summary OR 1.44 (95 % CI 1.17–1.77) for at 
least one GSTP1 105Val allele in case of total ethnic popu-
lation (Kellen et al. 2007).
Interestingly, our study shows that variant GSTT1 and 
GSTP1 genotypes were associated with reduced cancer 
risk, which in turn may suggest a complex role of these 
functional polymorphisms in BC development. We did not 
observed additional effect of smoking habit on the potential 
combined GSTP1 and GSTT1 polymorphism on BC risk 
when we stratified patients and controls into never, current 
and former smokers. In those three subgroups, GSTT1 null 
and GSTP1 Ile105Val + Val105Val combined genotype 
was associated with reduced BC risk, as it was observed 
in total group. It has been found that GSTT1 gene, under 
specific carcinogen exposure, plays a critical role in cancer 
development, due to important contribution of the conjuga-
tion reaction catalyzed by gstt1 to the formation of toxic 
metabolites, including dihaloalkanes (Monks et al. 1990). 
additionally, conformational changes of the gstP1 105Val 
alloenzyme may increase GSTP1 gene expression in human 
leukocytes and also contribute to more effective detoxifica-
tion efficacy of Pahs metabolites (Reszka et al. 2011). It 
should be noted that GSTP1 Ile105Val (rs1695) polymor-
phism was also found to be associated with the efficacy of 
cancer chemotherapy. lower risk of the disease progression 
and chemoresistance was found in GSTP1 105Val allele 
carriers (Romero et al. 2012) and also in cancer patients 
with at least one GSTP1 105Ile allele (Zhang et al. 2011a).
In the study of BC patients from central Poland, a sig-
nificant effect of GSTA1 −69t allele on BC risk was not 
observed, but frequency of homozygous carriers of this 
variant allele was lower in the BC patients than in the 
controls (13.6 vs. 17.3 %). to compare, in Japanese urothe-
lial cancer patients, also including BC patients, no associa-
tion between cancer risk and haplotype with minor GSTA1 
−69t allele was found (OR 1.22, 95 % CI 0.87–1.72) 
(Komiya et al. 2005). similarly, recent hospital-based case–
control study also indicates lack of association between BC 
risk and at least one GSTA1 −69t allele (OR 1.34, 95 % 
CI 0.82–2.20) (Matic et al. 2013). We also observed sig-
nificantly increased BC risk associated with GSTM1 null 
and GSTA1 −69Ct + −69tt genotype (OR 1.56, 95 % 
CI 1.08–2.26), which is in agreement with results from 
the previous study conducted in serbia, where smok-
ing carriers of those variant genotypes exhibited high risk 
of BC (OR 2.00, 95 % CI 0.83–4.81) (Matic et al. 2013). 
Indeed, the combination of variant gst genotypes may 
be associated with increased oxidative stress and there-
fore can increase BC risk. Recently, it was observed that 
oxidative Dna damage measured by urinary 8-hydroxy-
2′-deoxyguanosine level was modulated in relation to GST 
genotypes of BC patients. Combined GSTM1 null and 
GSTA1 −69Ct + −69tt genotype connected with low 
activity was associated with a twofold increase in that oxi-
dative damage (savic-Radojevic et al. 2013).
In the present study, we did not observe significant 
impact of SOD2 ala16Val polymorphism on BC risk. how-
ever, higher frequency of homozygotes with variant SOD2 
16Val allele was found in the controls (28.9 %) in compari-
son with the BC patients (24.6 %). association studies on 
SOD2 genetic polymorphism and BC risk showed incon-
sistent results. In the case–control study of Caucasians from 
northern Italy, SOD2 Val105Val genotype, associated with 
defective function of sOD2 enzyme, increased BC risk 
(OR 1.91, 95 % CI 1.20–3.04). additionally, an effect of 
minor SOD2 16Val allele on BC risk associated with smok-
ing (OR 7.20, 95 % CI 3.23–16.1) or Pahs exposure (OR 
3.02, 95 % CI 1.35–6.74) was found (hung et al. 2004). 
higher prevalence of SOD2 16Val alleles in control group 
was observed in the Us case–control study (terry et al. 
2005), Caucasians from ePIC cohort (Vineis et al. 2007) 
and two studies on turkish individuals (Cengiz et al. 2007; 
Kucukgergin et al. 2012), which may suggest protective 
role of SOD2 16Val allele in BC risk. similarly, reduced 
BC risk associated with SOD2 16Val alleles and GSTT1 
null genotype among non-smokers was also observed in the 
present study.
the role of transcription factor nRF2 in cancer etiol-
ogy, its development and treatment is still ambiguous and 
requires further research. additionally, nRF2 may affect 
resistance to common cytotoxic therapies in human cancers 
(hu et al. 2010). Moreover, when the activity of nRF2 is too 
high, it can lead to hyperplasia and increased susceptibility 
to atherosclerosis. this may serve as an evidence for the 
hormetic activity of the nRF2 transcription factor (Maher 
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and Yamamoto 2010). the low frequency of NRF2 −617a 
variant allele was observed in Caucasian population, includ-
ing Polish population (12 % in the present study). It was 
found that minor NRF2 −617a allele was significantly 
associated with oxidant-induced acute lung injury among 
patients of african and european descent with major trauma 
(Marzec et al. 2007), but it was not associated with gastric 
carcinogenesis in Japanese patients (arisawa et al. 2008) 
or colorectal adenomas in european patients (tijhuis et al. 
2008). In the present study, no association between NRF2 
polymorphism and BC risk was found. however, only four 
and eight BC individuals with NRF2 −617aa genotype in 
BC group and control group, respectively, were found. the 
present study may indicate association between NRF2 vari-
ants and GSTM1 and GSTP1 Ile105Val genetic polymor-
phisms, however, these interactions were not significant. 
Interestingly, when the effect of combined polymorphisms 
was generally uniform across the three strata describing 
smoking status, GSTP1 Ile105Val + Val105Val and NRF2 
−617Ca + −617aa genotypes significantly reduced BC 
risk in never smokers (OR 0.29, 95 % CI 0.08–0.98), while 
the combined GSTM1 null and NRF2 −617Ca + −617aa 
genotypes among current smokers were linked with signifi-
cantly higher BC risk (OR 2.52, 95 % CI 1.17–5.41).
the results of our study support the hypothesis concern-
ing significant impact of GSTM1 deletion on BC risk. We 
also found protective effect of GSTT1 deletion and GSTP1 
Val105Val genotype (rs1695) on BC risk and lack of such 
impact of GSTA1 −69C/t (rs3957357), SOD2 ala16Val 
(rs4880) and NRF2 −617C/a (rs6721961). additionally, 
gene–gene and gene–environment interactions modulat-
ing BC risk were observed for GSTT1 and GSTP1 geno-
type, GSTT1 and SOD2 genotype and smoking habit. tak-
ing into account several limitations of the study, including 
small sample size and selection bias of individuals from 
general population, these conclusions should be regarded 
with caution. In addition, the study was underpowered in 
terms of the assessment of moderate and small effects of 
minor alleles and of gene–gene and gene–environment 
interactions. however, the present study achieved power 
of at least 80 % to observe associations of the magnitude 
of OR 1.8 with GSTM1 null genotype frequency of about 
50 % and OR 0.5 with GSTT1 null genotype frequency of 
about 20 %. Further studies taking into account various 
confounding variables, such as adequate number of individ-
uals, study design and control selection, may explain still 
ambiguous results of investigations undertaken to clarify 
the correlation between NRF2 and nRF2-target genes poly-
morphisms and BC risk.
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